Decrease in Natalizumab Drug Levels After Switching From Intravenous to Subcutaneous Administration
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis
J. Neurol. Neurosurg. Psychiatr. 2023 Jan 13;[EPub Ahead of Print], AA Toorop, ZLE van Kempen, M Steenhuis, J Nielsen, LGF Sinnige, G van Dijk, CM Roosendaal, EPJ Arnoldus, E Hoitsma, BI Lissenberg-Witte, BA de Jong, BWV Oosten, EMM Strijbis, BMJ Uitdehaag, T Rispens, J KillesteinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.